AUROPHARMA

March 31 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - TO CONSIDER BUYBACK OF EQUITY SHARES

Source text: ID:nBSE9sWkfw

Further company coverage: ARBN.NS

(([email protected];))

March 20 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS UNIT-V API FACILITY OF APITORIA PHARMA, AUROBINDO SUBSIDIARY

• AUROBINDO PHARMA - UNIT-V RECEIVES EIR CLASSIFYING FACILITY AS VAI; INSPECTION CLOSED

Source text: ID:nBSE9t0t0d

Further company coverage: ARBN.NS

(([email protected];;))

March 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS TO EUGIA PHARMA UNIT-II

• US FDA CLASSIFIES EUGIA PHARMA UNIT-II AS 'OFFICIAL ACTION INDICATED'

Source text: ID:nNSE46tRKP

Further company coverage: ARBN.NS

(([email protected];;))

March 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• GETS TAX DEMAND AND PENALTY OF 776.1 MILLION RUPEES EACH

Source text: ID:nBSEbyqSK8

Further company coverage: ARBN.NS

(([email protected];))

March 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS UNIT-IV OF APL HEALTHCARE LIMITED

• AUROBINDO PHARMA - FORM 483 WITH 5 OBSERVATIONS ISSUED AFTER INSPECTION

Source text: ID:nBSE8pZVp3

Further company coverage: ARBN.NS

(([email protected];;))

March 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• EUGIA PHARMA LAUNCHES POMALIDOMIDE CAPSULES IN US

Source text: ID:nBSE9GK9VY

Further company coverage: ARBN.NS

(([email protected];;))

Feb 27 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• COMPLETION OF US FDA INSPECTION AT UNIT I OF EUGIA PHARMA SPECIALITIES

• INSPECTION CONCLUDED WITH 4 OBSERVATIONS

Further company coverage: ARBN.NS

(([email protected];))

Feb 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - EUGIA PHARMA RECEIVES USFDA APPROVAL FOR EVEROLIMUS TABLETS

• AUROBINDO PHARMA - LAUNCH EXPECTED IN Q1FY27

Source text: ID:nNSEbRhvzb

Further company coverage: ARBN.NS

(([email protected];))

Feb 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• TAX DEPARTMENT DEMANDS RECOVERY OF REFUNDS FROM AUROBINDO

• DISPUTED AMOUNT TOTALS 1.7 BILLION RUPEES

Source text: ID:nNSE6RP0n1

Further company coverage: ARBN.NS

(([email protected];;))

** HSBC raises Aurobindo Pharma ARBN.NS PT from 1,380 rupees to 1,415 rupees, maintains "buy"

** Hike comes after US FDA approves Adquey, a non-steroid topical treatment for dermatitis

** Says Adquey has potential to become a $250-300 million brand and that ARBN needs to hire specialist salespeople

** Entry in next 6-7 months could help it capture share in a supply‑constrained category with strong prescription demand - HSBC

** ARBN up 1% at 1,157 rupees since Friday, when FDA approval was received

** 26 analysts covering ARBN have "buy" rating on avg; median PT is 1,380 rupees - data compiled by LSEG

** YTD, stock down 2.5%

(Reporting by Urvi Dugar in Bengaluru)

(([email protected]; +91 9558725583;))

Feb 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FDA APPROVES ADQUEY FOR ATOPIC DERMATITIS

Source text: ID:nBSE9QTPmX

Further company coverage: ARBN.NS

(([email protected];))

** Shares of Aurobindo Pharma ARBN.NS fall around 8% to 1,106 rupees, its lowest since Oct. 31

** Stock set for its worst day since November 2022

** Pharma co posts 7.6% rise in Q3 profit to 9.1 billion rupees; consol rev rises 8.4% y/y

** Citi Research says Q3 beat was largely driven by favourable currency, continued strength in Europe

** Adds, co's flagship US generics business remains subdued

** More than 5.4 mln shares traded, 4.5x their 30-day avg

** YTD, ARBN down to ~6%

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Feb 9 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA Q3 CONSOL NET PAT 9.1 BILLION RUPEES

• AUROBINDO PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 86.46 BILLION RUPEES

Source text: ID:nNSE3S9nzx

Further company coverage: ARBN.NS

(([email protected];;))

Feb 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTED UNIT-III OF EUGIA PHARMA

• AUROBINDO PHARMA - INSPECTION CONCLUDED WITH 11 PROCEDURAL OBSERVATIONS

Source text: ID:nNSE82jtld

Further company coverage: ARBN.NS

(([email protected];))

** Shares of India's Aurobindo Pharma ARBN.NS jump 4.28% to 1200.10 rupees

** Citi ("sell", PT: 1010 rupees) says India's minimum import price on penicillin-G removes uncertainty, lifting pricing visibility for domestic producers - note

** Brokerage adds the move could help improve utilisation at Aurobindo's penicillin-G plant which has been underutilized due to Chinese competition

** Trading volumes at 3.09 mln shares vs 30-day average of 800,425 shares

** Stock rated "buy" on avg by 25 analysts, median PT at 1337.50 rupees -- data compiled on LSEG

** ARBN dropped 11.35 in 2025, stock down ~2.7% in Jan

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Jan 23 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - SUBSIDIARY INCORPORATED A NEW WHOLLY OWNED SUBSIDIARY IN PHILIPPINES

Source text: ID:nBSE4DzcXY

Further company coverage: ARBN.NS

(([email protected];))

** U.S. FDA approves application for generic version of GSK's Advair inhaler by partner of Aurobindo Pharma-owned ARBN.NS Lannett, Citi says

** Brokerage sees generic Advair adding $30 mln-$40 mln to co's annual U.S. revenues

** Notes additional competition from Aurobindo Pharma "marginal negative" for rival Cipla CIPL.NS, which expects FDA approval for gAdvair in near-term

** Adds Advair seen contributing $50 million to Cipla's U.S. revenue in FY27

** Aurobindo Pharma gets more than 50% of annual revenue from U.S.; Cipla earns ~29% from North America (mostly U.S.)

** Aurobindo Pharma said it would buy U.S.-based Lannett last year at enterprise value of $250 million

** ARBN down 0.6%; CIPL down 1.4%, second-biggest pct loser on Nifty 50 .NSEI

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Jan 9 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ RECEIVES NOC FROM CANADA HEALTH AUTHORITY FOR BIOSIMILAR DYRUPEG

Source text: ID:nNSE4n1MtQ

Further company coverage: ARBN.NS

(([email protected];))

Jan 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• TO BUY NON-ONCOLOGY PRESCRIPTION FORMULATIONS BUSINESS OF KHANDELWAL LABORATORIES

• CASH CONSIDERATION OF 3.25 BILLION RUPEES FOR ACQUISITION

Further company coverage: ARBN.NS

(([email protected];))

By Khushi Malhotra and Dharamraj Dhutia

MUMBAI, Oct 7 (Reuters) - India's Auro Realty, the real estate arm of Aurobindo Group which also owns drugmaker Aurobindo Pharma ARBN.NS, is planning to raise 20 billion rupees ($225.41 million) through the sale of bonds to fund a key acquisition, two merchant bankers said on Tuesday.

Auro Realty is looking to issue two-year and four-year bonds, with the coupons ranging from 11%-15%, the bankers added.

"It is a promoter-level financing to acquire some of the assets, including Hotel Taj Banjara Hyderabad," one of the bankers said.

The group did not reply to a Reuters email seeking comment, while the bankers requested anonymity as they are not authorised to speak to the media.

Auro Realty's bond issue is in advanced stages and could be completed as early as this month, while private credit funds are expected to be investors, the bankers added.

The bond issue adds to a rising trend of firms tapping the corporate bond market to fund large acquisitions.

($1 = 88.7275 Indian rupees)

(Reporting by Khushi Malhotra and Dharamraj Dhutia; Editing by Eileen Soreng)

(([email protected];))

Sept 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - SMALL FIRE INCIDENT OCCURRED IN GRANULATION AREA-10 OF UNIT IV OF APL HEALTHCARE

• AUROBINDO PHARMA LTD - 2 LINES IMPACTED FOR ABOUT TWO WEEKS

• AUROBINDO PHARMA LTD - NO CASUALTIES OR INJURIES REPORTED

• AUROBINDO PHARMA LTD - TEMPORARY PRODUCTION IMPACT ESTIMATED AT 3% OF CAPACITY

• AUROBINDO PHARMA LTD - REFURBISHMENT INITIATED, OPERATIONAL IN NEXT FEW WEEKS

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Adds deal value from source in paragraph 2, background on Zentiva and previous deal reports from paragraph 4 onwards

Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.

The deal values the Prague-based company at slightly more than 4 billion euros ($4.69 billion) including debt, according to a source with knowledge of the deal.

The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros.

Zentiva was acquired by Advent from French pharmaceutical giant Sanofi SASY.PA in 2018 for an enterprise value of 1.9 billion euros.

There have been reports of Advent mulling a sale of the generics drugmaker since 2021, with companies such as Polish drugmaker Polpharma and India's Aurobindo Pharma ARBN.NS reported to be joining the race.

Zentiva supplies a wide range of generic and over-the-counter drugs such as paracetamol and co-codamol to more than 100 million people across Europe.

($1 = 0.8530 euros)

(Reporting by Unnamalai L in Bengaluru and Andres Gonzalez Estebaran; Editing by Maju Samuel)

(([email protected];))

Sept 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - COMPLETION OF US FDA INSPECTION AT UNIT-XII OF AUROBINDO PHARMA

• AUROBINDO PHARMA - TOTAL OF 8 OBSERVATIONS ISSUED BY FDA

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here

By Nancy Lapid

Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.

Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.

“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.

Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.

Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.

The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.

“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.

Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.

RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS

Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.

In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.

The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.

A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.

There were no device malfunctions in either group.

The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.

“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.

“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.

Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.

(To receive the full newsletter in your inbox for free sign up here)

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

(([email protected]))

Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here

By Nancy Lapid

Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.

Clopidogrel tops aspirin for routine use in heart patients

The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.

Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.

“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.

Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.

Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.

The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.

“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.

Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.

Recycled pacemakers improve access in low-income nations

Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.

In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.

The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.

A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.

There were no device malfunctions in either group.

The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.

“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.

“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.

Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

(([email protected]))

Aug 26 (Reuters) - Aurobindo Pharma ARBN.NS:

• CURATEQ BIOLOGICS RECEIVES MHRA APPROVAL FOR DAZULBYS

Source text: ID:nNSE1Ys71d

Further company coverage: ARBN.NS

(([email protected];))

Adds details, shares in paragraphs 2-4; fair comment in paragraph 5

Aug 20 (Reuters) - India's Aurobindo Pharma ARBN.NS is leading the race to buy Prague-based drugmaker Zentiva 1SKF401E.BV for up to $5.5 billion, the Economic Times reported on Wednesday, in what could be the largest-ever acquisition by an Indian pharmaceutical firm.

Aurobindo is in talks with Zentiva's owner U.S.-based private equity firm Advent International, the report said, citing people aware of the matter.

However, Aurobindo, in a statement to exchanges, said no binding agreements have been signed by the company's board.

The company's shares slid as much as 4.7% in early trade after the report, before trimming it to 3.7% lower.

Advent International and Zentiva declined to comment on the report.

(Reporting by Kashish Tandon in Bengaluru; Editing by Harikrishnan Nair)

(([email protected]; 8800437922;))

** Shares of Aurobindo Pharma ARBN.NS fall as much as 2.7% to 1060.90 rupees

** Pharma co posts 10% y/y drop in June-qtr consol net PAT, expenses rise 5%

** ARBN rev rose 4% but missed analysts' expectations of Macquarie and Motilal Oswal

** Macquarie said revenue miss was driven by lower than expected revenue from the U.S. business

** Adds, muted growth in co's "bread and butter" U.S. business worrisome

** More than 2.5 mln shares traded, 2x their 30-day avg

** Stock last down 1%, taking YTD losses to 18%

(Reporting by Nishit Navin in Bengaluru)

(([email protected]))

Aug 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• Q1 CONSOL NET PROFIT 8.25 BILLION RUPEES

• Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 78.68 BILLION RUPEES

• DIVIDEND 4 RUPEES PER SHARE

Further company coverage: ARBN.NS

(([email protected];;))

Aug 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CLARIFIES REPORT TRUMP SHOOTS LETTERS TO GLOBAL DRUG MAJORS

• AUROBINDO PHARMA - NOT RECEIVED ANY COMMUNICATION AS PER MEDIA

Source text: ID:nBSEbwpshz

Further company coverage: ARBN.NS

(([email protected];))